期刊文献+

艾本治疗恶性肿瘤骨转移的临床研究 被引量:6

Clinical study on the effect of Aiben in treatment of malignant bone metastasis.
下载PDF
导出
摘要 目的观察艾本对恶性肿瘤骨转移疼痛和转移灶的治疗效果。方法对恶性肿瘤骨转移者静脉应用艾本4mg,每月1次,1个月为1周期,至少2周期后评价疗效及不良反应,疗效评价指标包括止痛效果、KPS评分的变化和转移灶的改变情况。结果疼痛完全缓解14例,有效31例,无效7例,有效率86.54%;KPS评分提高的中位数为10;骨转移灶CR2例,PR9例,MR12例,总有效率44.23%;不良反应为发热、恶心及腹胀,发生率低。结论艾本对骨转移引起的疼痛有良好的止痛效果,对转移灶有较好的治疗作用,副作用少,值得临床应用。 Objective To observe the efficacy of Aiben to treat metastatic bone and to relieve pain. Methods Aiben 4 mg was given by infusion, the treatment was repeated at 1 month intervals, the effect and toxicity were evaluated after at least 2 cycles . The evaluated target included the relieving pain.the change of KPS and the change of metastatic focus. Results Complete relief of pain was in 14 patients, partrial relief 31 patients, no effect 7 patients with a total effective rate of 86.54% ; KPS rised median 10; Among these patients with metastatic bone ,complete response 2, partial response 9, miscro response 12, the total effective rate was 44.23% ; The toxicity reactions were fever. nausea and abdominal distention, but the rate was low. Conclusion Aiben is effective to relieve the pain of metastatic bone cancer and is effective to treat metastatic focus, the side effect can be tolerated . It can be used in clinic.
出处 《现代肿瘤医学》 CAS 2005年第5期667-668,共2页 Journal of Modern Oncology
关键词 艾本 止痛 恶性肿瘤 骨转移 Aiben relief of pain malignant tumor bone metastasis
  • 相关文献

参考文献5

二级参考文献14

  • 1廖开莲,易立正,肖立新,殷先利,彭旭阳,袁志军,朱跃红.骨膦治疗恶性肿瘤骨转移22例临床应用总结[J].中国肿瘤临床,1997,24(2):158-159. 被引量:17
  • 2[1]Ravn P,Clemmesen B,Riis BJ,et al.The effect on bone mass and bone markers of different doses of ibandronate:a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis:a-lyear,randomized,double-blind,placebo-controlled does-finding study[J].Bone,1996,19(5):527~533.
  • 3[2]Thiebaud D,Burckhardt P,Kriegbaum H,et al.Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis[J].Am J Med,1997,103(4):298~307.
  • 4[3]WCO:New data released for ibandronate in postmenopausal women with osteoporosis[C].Lisbon,Portugal,2002.
  • 5[4]Woitge HW,Oberwittler H,Heichel S,et al.Short-and long-term effects of ibandronate treatment on bone turnover in paget disease of bone[J].Clin Chem,2000.46(5):684~690.
  • 6[5]Fleisch H.Bisphosphonates in bone disease[M].San Diego:Academic Press,2000,12~16,36~45.
  • 7[6]Dooley M,Balfour JA.Ibandronate[J].Drugs,1999,57(1):101~110.
  • 8Green JR, Muller K, Jageggi KA Preclinical Pharmacology of CGP42446. a new: Potent, heterocyclic bispbosphonate compound[J]. J Bone Miner Res. 1994;9(5):745 -751.
  • 9Coleman RE. Purohit OP. Black C, et al. I bandronate: a well toierated new oral bisphosphonate for the treatment of bone metastases[J].Breast, 1995;4(9) :236.
  • 10Jeal W, Barradell LB, Mctavish D. Alendronste: a review of it pharmcologocal properties and therapeutic efficacy in postmentopausal osteoporosis[J]. Drugs, 1997;53(3):415.

共引文献15

同被引文献57

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部